July 01 2024 05:02:15 — It is official now, after the initial announcement in April: Wolfgang Wienand becomes CEO of Lonza Group, succeeding Albert M. Baehny.
Lonza, a major healthcare manufacturer, generated CHF 6.7 billion in sales in 2023.
Wolfgang has a strong background in leadership roles within the pharmaceutical and chemicals industries, with significant experience in both scientific and strategic areas. His career path shows a steady progression of increasing responsibility and leadership.
Jean-Marc Huët, Chairman, welcomes Wolfgang, who brings extensive CDMO experience. A CDMO provides comprehensive services from drug development through drug manufacturing.
Wolfgang, previously CEO at Siegfried, aims for growth and meeting customer needs.